Capricor Therapeutics Announces Intent To File Biologics License Application For Full Approval Of Deramiocel For The Treatment Of Duchenne Muscular Dystrophy Cardiomyopathy
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics plans to file a Biologics License Application (BLA) for deramiocel, targeting Duchenne muscular dystrophy cardiomyopathy. The BLA will be supported by existing cardiac data and a rolling submission is set to begin in October 2024.
September 24, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics announced plans to file a BLA for deramiocel, aiming for full approval to treat Duchenne muscular dystrophy cardiomyopathy. The submission will start in October 2024, supported by existing cardiac data.
The announcement of a BLA filing for deramiocel is a significant step for Capricor Therapeutics, potentially leading to full approval for treating DMD cardiomyopathy. This could enhance the company's market position and drive stock price upward.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100